ArticleNature communications2023
High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal of nanobiotechnology · 2026Pooled it
- Empowering clinical trial design with agentic intelligence and real-world data.Nature communications · 2026Article
- Neural networks and econometric models: Advancing brain connectivity for Alzheimer's drug development.Neural regeneration research · 2026Article
- Integrating genetically predicted transcriptomic signatures with longitudinal real-world data enables scalable drug repurposing for Alzheimer's disease.Research square · 2026Article
- A Latent Variable Approach for Causal Effect Estimation Under Misclassified Treatment Assignment.Statistics in medicine · 2026Article
- Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention.American journal of human genetics · 2026Article
- Harnessing patient health data to benefit individuals and advance research: a focus on rheumatoid arthritis - a narrative review.BMJ digital health & AI · 2026Review
- molIEreVIS: exploring and interpreting the evidence behind drug repurposing predictions.Frontiers in bioinformatics · 2026Article
- Artificial intelligence and machine learning for precision prevention of cognitive decline: integrating multimodal biomarkers, lifestyle interventions, and natural medicines from prediction to clinical practice.Frontiers in aging neuroscience · 2026Review
- Artificial Intelligence to Guide Repurposing of Drugs.Annual review of medicine · 2026Review
- MOSIC: Model-Agnostic Optimal Subgroup Identification with Multi-Constraint for Improved Reliability.KDD : proceedings. International Conference on Knowledge Discovery & Data Mining · 2026Article
- CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease.Research square · 2025Article
- The role for artificial intelligence in identifying combination therapies for Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Review
- Decoding the genomic symphony: unravelling brain disorders through data integration and machine learning.Molecular psychiatry · 2025Review
- Alzheimer Combination Therapies: Overview and Scenarios.The journal of prevention of Alzheimer's disease · 2025Review
- Medical risk factors, ApoE haplotype, and Alzheimer's disease: a large-scale analysis.The journal of prevention of Alzheimer's disease · 2025Article
- The first causal inference analysis of the Catalan Arthroplasty Register shows a positive effect of antibiotic-loaded bone cement on knee prosthesis survival.Journal of experimental orthopaedics · 2025Article
- A computational medicine framework integrating multi-omics, systems biology, and artificial neural networks for Alzheimer's disease therapeutic discovery.Acta pharmaceutica Sinica. B · 2025Article
- Proinflammatory transcriptomic and kinomic alterations in astrocytes derived from patients with familial Alzheimer's disease.Brain, behavior, & immunity - health · 2025Article
- A Deep Subgrouping Framework for Precision Drug Repurposing via Emulating Clinical Trials on Real-world Patient Data.KDD : proceedings. International Conference on Knowledge Discovery & Data Mining · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Target trial emulation is the process of mimicking target randomized trials using real-world data, where effective confounding control for unbiased treatment effect estimation remains a main challenge. Although various approaches have been proposed for this challenge, a systematic evaluation is still lacking. Here we emulated trials for thousands of medications from two large-scale real-world data warehouses, covering over 10 years of clinical records for over 170 million patients, aiming to identify new indications of approved drugs for Alzheimer's disease. We assessed different propensity score models under the inverse probability of treatment weighting framework and suggested a model selection strategy for improved baseline covariate balancing. We also found that the deep learning-based propensity score model did not necessarily outperform logistic regression-based methods in covariate balancing. Finally, we highlighted five top-ranked drugs (pantoprazole, gabapentin, atorvastatin, fluticasone, and omeprazole) originally intended for other indications with potential benefits for Alzheimer's patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.